Sarcopenia: Relevance, Epidemiology, Etiopathogenesis, Histological Characteristics, and Modern Treatment Approaches
Abstract
The study aimed to conduct a comprehensive theoretical analysis of modern concepts regarding the etiopathogenesis and pathomorphological mechanisms of sarcopenia development. The goal was to update the understanding of the systemic and generalized nature of this condition as a multisystem disorder affecting skeletal muscles and integrated body systems. An information search was performed across major databases, including PubMed, Scopus, Embase, Web of Science, and Google Scholar. The study analyzed sources published between 2016 and 2026, focusing on the pathomorphological mechanisms, classification, and methods of correction for sarcopenia. Sarcopenia is identified as a multifactorial state characterized by a transition from healthy muscle architecture to qualitative degradation. Key findings include: Sarcopenia is divided into primary (age-related) and secondary (associated with chronic diseases, such as heart failure or HIV, and lifestyle factors). The condition involves selective atrophy of Type II (fast-twitch) muscle fibers, while Type I fibers remain relatively intact. Pathogenesis includes myosteatosis (fatty infiltration) driven by fibro-adipogenic progenitors (FAPs), myofibrosis (excessive collagen synthesis), and the fragmentation of neuromuscular junctions (NMJ). A critical decline in the number and proliferative potential of satellite cells (MuSCs) prevents effective muscle repair. Systemic inflammation ("inflammaging"), oxidative stress, and hormonal imbalances (deficit of IGF-1 and anabolic hormones) drive the catabolic shift. Sarcopenia is a complex, systemic disease that extends far beyond simple age-related muscle loss. It represents a profound structural and functional degradation characterized by fiber atrophy, fatty and fibrous replacement, and impaired neuromuscular transmission. Effective clinical management requires a multisystemic approach that targets molecular and cellular mechanisms alongside lifestyle and nutritional interventions.
References
Mao X, Lv K, Qi W, Cheng W, Li T, Sun Y, et al. Progress in sarcopenia research in the musculoskeletal system. Bone Res. 2025 Sep 23;13(1):78. doi: 10.1038/s41413-025-00455-8. PMID: 40987776; PMCID: PMC12457612.
Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023 Jul;144:155533. DOI: 10.1016/j.metabol.2023.155533. PMID: 36907247.
Cho MR, Lee S, Song SK. A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction. J Korean Med Sci. 2022 May 9;37(18):e146. doi: 10.3346/jkms.2022.37.e146. PMID: 35535373; PMCID: PMC9091430.
Sayer AA, Cooper R, Arai H, Cawthon PM, Ntsama Essomba MJ, Fielding RA, et al. Sarcopenia. Nat Rev Dis Primers. 2024 Sep 19;10(1):68. DOI: 10.1038/s41572-024-00550-w. PMID: 39300120.
Supriya R, Singh KP, Gao Y, Gu Y, Baker JS. Effect of Exercise on Secondary Sarcopenia: A Comprehensive Literature Review. Biology (Basel). 2021 Dec 30;11(1):51. https://doi.org/10.3390/biology11010051. PMID: 35053049; PMCID: PMC8773430.
Therakomen V, Pethlorlian A, Lakananurak N. Prevalence and Risk Factors of Primary Sarcopenia in Community-Dwelling Outpatient Elderly: A Cross-Sectional Study. Sci Rep. 2020 Nov 11;10(1):19551. doi: 10.1038/s41598-020-75250-y. PMID: 33177536; PMCID: PMC7658996.
Guo Z, Li H, Jiang S, Rahmati M, Su J, Yang X, et al. The Role of AGEs in Muscle Aging and Sarcopenia. Bone Joint Res. 2025 Mar 4;14(3):185-198. 10.1302/2046-3758.143.BJR-2024-0252.R1. PMID: 40036085; PMCID: PMC11878473.
Barone M, Baccaro P, Molfino A. A Review of Sarcopenia: Focus on Nutritional Management Approaches. Nutrients. 2025 Apr 1;17(7):1237. doi: 10.3390/nu17071237. PMID: 40218995; PMCID: PMC11990658.
Prokopidis K, Triantafyllidis KK, Kechagias KS, Mitropoulos A, Sankaranarayanan R, Isanejad M. Are sarcopenia and its individual components associated with all-cause mortality in heart failure? A systematic review and meta-analysis. Clin Res Cardiol. 2025 May;114(5):532-540. doi: 10.1007/s00392-023-02360-8. PMID: 38085294; PMCID: PMC12058882.
Seyeadalinagi S, Ghaemzadeh M, Mirzapour P, Maroufi SF, Pashaei Z, Ali Z, et al. Systematic review of the prevalence of sarcopenia and related factors in people living with human immunodeficiency virus. J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1168-1182. doi: 10.1002/jcsm.13212. PMID: 36929581; PMCID: PMC10235901.
Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. Clin Cases Miner Bone Metab. 2014 Sep;11(3):177-80. PMID: 25568649; PMCID: PMC4269139.
Dhillon RJ, Hasni S. Pathogenesis and Management of Sarcopenia. Clin Geriatr Med. 2017 Feb;33(1):17-26. doi: 10.1016/j.cger.2016.08.002. PMID: 27886695; PMCID: PMC5127276.
Bodin SC, Sinha I, Sweeney HL. Mechanisms of Skeletal Muscle Atrophy and the Molecular Circuitry of Stem Cell Fate in Skeletal Muscle Regeneration and Aging. J Gerontol A Biol Sci Med Sci. 2023 Jun 16;78(Suppl 1):14-18. doi: 10.1093/gerona/glad023. PMID: 37325966; PMCID: PMC10272973.
Kaisar R, Ahmad F, Karim A. The Neuromuscular Junction as a Molecular Target in Sarcopenia: Mechanisms, Therapeutic Strategies, and Future Directions. Mol Diagn Ther. 2026 Mar;30(2):321-335. DOI: 10.1007/s40291-026-00833-w. PMID: 41619083.
Talbot J, Maves L. Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease. Wiley Interdiscip Rev Dev Biol. 2016 Jul;5(4):518-34. doi: 10.1002/wdev.230. PMID: 27199166; PMCID: PMC5180455.
Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E151-7. DOI: 10.1152/ajpendo.00278.2006. PMID: 16926381.
He H, Liu K, Liu X. Contribution of Muscle Satellite Cells to Sarcopenia. Front Physiol. 2022 Aug 12;13:892749. doi: 10.3389/fphys.2022.892749. PMID: 36035464; PMCID: PMC9411786.
Chow SK, van Mourik M, Hung VW, Zhang N, Li MM, Wong RM, et al. HR-pQCT for the Assessment of Muscle Quality and Intramuscular Fat Infiltration in Aging Skeletal Muscle. J Pers Med. 2022 Jun 20;12(6):1016. doi: 10.3390/jpm12061016. PMID: 35743800; PMCID: PMC9225354.
Wang L, Valencak TG, Shan T. Fat infiltration in skeletal muscle: Influential triggers and regulatory mechanisms. iScience. 2024 Feb 15;27(3):109221. doi: 10.1016/j.isci.2024.109221. PMID: 38433917; PMCID: PMC10907799.
Jones HG, Kopinke D, Meyer GA. Внутрішньом'язова жирова тканина: від предка до патології. Am J Фізіотерапевт фізіологічних клітин 2025 1 жовтня; 329(4):C1268-C1282. doi: 10.1152/ajpcell.00613.2025. Epub 2025, 15 вересня. PMID: 40953040; PMCID: PMC12486183.
Chun SI, Choi KM. The influence of adipose tissue and lipids on skeletal muscle in sarcopenia. J Cachexia Sarcopenia Muscle. 2025;16(4):e70000. doi: 10.1002/jcsm.70000. PMID: 40641114; PMCID: PMC12246390.
Li Y, Guo W, Li H, Wang Y, Liu X, Kong W. Inflammation-induced skeletal muscle change in obesity as a key path to fibrosis: insights into mechanisms and intervention strategies. Biomolecules. 2024 Dec 27;15(1):20. doi: 10.3390/biom15010020. PMID: 39858415; PMCID: PMC11764331.

This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN
ISSN 














